Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3145095 in Advanced Solid Tumors
NCT03681951Phase 2Terminated
- Sponsor
- GSK
- Start
- Nov 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GSK3145095 in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 2 more (4 arms), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With AEs by Severity Grades and 2 more. Started Nov 2018; status: terminated.
02
Drugs
GSK3145095
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)melanomasolid tumor
Beyond the preview
Go deeper on NCT03681951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681951.